BIOGEN INC. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31)
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) of $2.14 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-01.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesTaxEffectPeriodIncreaseDecrease · last filed 2012-05-01
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $2.14M, a 5.26% increase year-over-year.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $2.31M.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $3.80M, a 52.50% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $800.00K, a 77.78% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2011 was $4.92M, a 409.85% increase from fiscal 2010.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2010 was $964.00K, a 73.09% decline from fiscal 2009.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2009 was $3.58M, a 135.35% increase from fiscal 2008.
- BIOGEN INC. other comprehensive income (loss), derivatives qualifying as hedges, tax effect (deprecated 2012-01-31) for fiscal 2008 was $1.52M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Effect (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $2.14M 10-Q · filed 2012-05-01 | $4.46M derived: sum of 2 quarters · filed 2012-05-01 | $8.26M derived: sum of 3 quarters · filed 2012-05-01 | $9.06M derived: sum of 4 quarters · filed 2012-05-01 |
| 2011-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $6.12M derived: sum of 2 quarters · filed 2012-02-03 | $6.92M derived: sum of 3 quarters · filed 2012-02-03 | $4.92M 10-K · filed 2012-02-03 |
| 2011-09-30 | $3.80M 10-Q · filed 2011-10-28 | $4.60M derived: sum of 2 quarters · filed 2011-10-28 | $2.60M 10-Q · filed 2011-10-28 | $6.10M derived: sum of 4 quarters · filed 2012-05-01 |
| 2011-06-30 | $800.00K 10-Q · filed 2011-07-26 | $1.20M 10-Q · filed 2011-07-26 | $2.30M derived: sum of 3 quarters · filed 2012-05-01 | $10.30M derived: sum of 4 quarters · filed 2012-05-01 |
| 2011-03-31 | $2.04M 10-Q · filed 2012-05-01 | $1.50M derived: sum of 2 quarters · filed 2012-05-01 | $9.50M derived: sum of 3 quarters · filed 2012-05-01 | $13.10M derived: sum of 4 quarters · filed 2012-05-01 |
| 2010-12-31 | -$536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $7.46M derived: sum of 2 quarters · filed 2012-02-03 | $11.06M derived: sum of 3 quarters · filed 2012-02-03 | $964.00K 10-K · filed 2012-02-03 |
| 2010-09-30 | $8.00M 10-Q · filed 2011-10-28 | $11.60M derived: sum of 2 quarters · filed 2011-10-28 | $1.50M 10-Q · filed 2011-10-28 | |
| 2010-06-30 | $3.60M 10-Q · filed 2011-07-26 | $6.50M 10-Q · filed 2011-07-26 | ||
| 2009-12-31 | $3.58M 10-K · filed 2012-02-03 | |||
| 2008-12-31 | $1.52M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |